Cocaine/Metabolites Screen

You might be checking an unexpected result, monitoring recovery, or trying to understand a required drug test. This urine screen looks for benzoylecgonine after cocaine exposure. It's an established exposure test, but a positive result cannot establish the dose, exact time of use, or whether you're currently impaired.

What the Screen Picks Up

Your body breaks cocaine down into several compounds. Benzoylecgonine is the main target of routine urine screening because it usually remains detectable longer than cocaine itself. Ecgonine methyl ester is another major breakdown product, but this screen does not separately report it.

This is a qualitative immunoassay. It uses antibodies to detect benzoylecgonine and reports a positive or negative result. It does not report a concentration you can track.

A positive screening result is presumptive until confirmed. Confirmation uses a separate laboratory method to identify the specific substance more reliably. The usual methods combine chromatography with mass spectrometry and appear on reports as LC-MS/MS or GC-MS. They separate compounds and identify them from characteristic molecular signals; some also report the amount present.

Why Detection Can Outlast the Drug's Effects

Cocaine's effects wear off before all its breakdown products leave your body. The detection window depends on the amount taken, how often exposure occurred, individual elimination, urine concentration, and the sensitivity of the assay. A time estimate is never a guarantee of when a particular sample will become negative.

Repeated heavy use can prolong elimination. In a study that collected every urine sample from chronic users staying on a closed research unit, results sometimes became positive again after an initial negative despite no opportunity for new use. Adjusting concentrations for urine creatinine did not eliminate these fluctuations.

What the Heart Findings Show

Cocaine exposure can harm the heart. Troponin is a protein released into blood when heart muscle cells are injured. A troponin result needs symptoms and other findings to establish the cause of that injury.

In a hospital study of 200 adults receiving care for noncardiac problems, a cocaine-positive urine screen was associated with nearly three times the adjusted odds of detectable troponin I compared with a cocaine-negative screen. This was a small observational study, and its estimate was imprecise.

The finding supports concern about heart injury outside an obvious cardiac emergency. It does not establish that routine high-sensitivity troponin testing improves outcomes in everyone with a positive drug screen. This urine result also cannot diagnose heart damage or estimate your personal heart attack risk.

Long-Term Risk After a Positive Screen in Adolescence

A records-based study followed 2,772 people who had urine drug testing as teenagers for about 12 years. A cocaine-positive result was associated with more deaths from external causes, including overdoses and accidents. The unadjusted estimate was about sevenfold, but it rested on only three deaths among the 58 people who had tested positive for cocaine.

The association remained after adjustment for several measured differences between groups. It identifies a group that may need support, but it doesn't show that cocaine caused those deaths or predict what will happen to an individual teenager. The study examined risk over many years.

Other Substances Can Accompany Exposure

A study of one million clinical urine specimens found that nonprescribed fentanyl became more common among cocaine-positive specimens between 2013 and 2018. Researchers used mass spectrometry to identify benzoylecgonine and fentanyl-related compounds separately. Finding both establishes exposure to both substances, but cannot distinguish intentional combined use from unexpected contamination.

Another analysis of about 922,000 urine specimens found that measured cocaine-related concentrations increased between 2013 and 2023. These were quantitative measurements of urinary benzoylecgonine, adjusted for creatinine. They cannot establish the purity of a drug supply or the dose taken by an individual.

Levamisole has also been found in cocaine supplies. In a French hospital study conducted in 2014, separate testing detected it in 76% of 42 cocaine-positive urine samples from 39 people. That local finding should not be treated as a current contamination rate everywhere.

This screen does not test for fentanyl or levamisole. A standard morphine/opiates screen also misses fentanyl, which requires a separate test.

Alcohol and Liver Scarring

Using cocaine and alcohol together can produce cocaethylene in the liver. This compound has drug effects of its own and is different from the benzoylecgonine targeted by this urine screen.

In a cross-sectional study of 649 people living with and without HIV, cocaethylene detected in blood was associated with higher odds of a blood-test score suggesting liver fibrosis. Fibrosis is scarring of liver tissue. The study used the FIB-4 score rather than directly measuring scarring in every participant, and it could not establish that cocaethylene caused the finding. A positive urine cocaine screen alone does not establish simultaneous alcohol use or liver fibrosis.

Brain Findings Use Different Measurements

Research using brain scans in people with diagnosed cocaine or methamphetamine use disorder has found differences in several brain chemicals. Some patterns resemble those reported in cognitive impairment and Alzheimer's disease. These are measurements of brain chemistry, separate from urinary benzoylecgonine. The findings do not establish that a positive urine screen predicts dementia.

Exposure and Current Illness Are Different Questions

In a study of 111 emergency patients, blood concentrations of cocaine and its metabolites did not reliably predict symptom severity, complications, or treatment needs. Those blood measurements differ from this urine screen, but the study illustrates why toxicology results must be interpreted with the person's condition.

A separate study enrolled 328 people with a history of cocaine use who were having elective noncardiac surgery. Among those without symptoms and with normal vital signs and an electrocardiogram, cocaine-positive and cocaine-negative groups had similar proportions of time with blood pressure or heart rate outside the study's limits during anesthesia. This finding applies to that selected surgical population and does not establish safety during acute intoxication.

When Results Can Be Misleading

• False positives: cocaine immunoassays are relatively specific, but false-positive results have been documented. Antibody interference and analytical errors are reasons an unexpected result needs confirmation.
• False negatives: exposure can be missed if collection occurs before enough benzoylecgonine appears, after it has cleared, or when urine is very dilute. A more sensitive confirmation assay can detect exposure that a screen misses.
• Testing only the metabolite: in a study of 7,587 urine specimens positive for cocaine or benzoylecgonine by mass spectrometry, 3% contained cocaine without detectable benzoylecgonine. A benzoylecgonine-focused screen can miss this pattern.
• Medical or dietary exposure: medical cocaine and coca-leaf tea can produce genuine positive results. The test cannot determine whether exposure was recreational, medical, or unintentional.
• Urine concentration: hydration affects the amount of metabolite per volume of urine. Urine creatinine and specific gravity can help identify dilution, but this qualitative screen is not automatically a creatinine-adjusted concentration.
• Carryover after heavy use: a positive following a negative can occur while old exposure is still clearing. That sequence alone does not prove renewed use.

What Repeated Results Can Show

Repeated qualitative screens can document a pattern of detected and undetected exposure during recovery. They cannot show whether a metabolite concentration is rising or falling. Separate quantitative testing can sometimes help interpret carryover, but neither an increase nor a decrease establishes new use or abstinence on its own.

Research programs have used changes in quantitative urine benzoylecgonine to recognize periods of likely abstinence while samples remain positive. Interpretation depends on the time between collections and the rules used, and creatinine adjustment does not remove all biological variation.

In pooled treatment trials, participants who provided mostly cocaine-negative urine samples had better treatment retention and subsequent substance-use and functioning outcomes, with follow-up extending to a year. Separate analyses of cocaine and methamphetamine treatment trials found that reduced self-reported use was associated with improvements even without complete abstinence. These findings support assessing recovery through both testing and changes in your daily life.